Compare TIVC & PPCB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TIVC | PPCB |
|---|---|---|
| Founded | 2016 | 2007 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8M | 3.2M |
| IPO Year | 2021 | N/A |
| Metric | TIVC | PPCB |
|---|---|---|
| Price | $0.81 | $0.17 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 31.1K | ★ 1.5M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $780,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.75 | $0.16 |
| 52 Week High | $13.20 | $10.69 |
| Indicator | TIVC | PPCB |
|---|---|---|
| Relative Strength Index (RSI) | 34.39 | 30.69 |
| Support Level | $0.76 | $0.16 |
| Resistance Level | $1.36 | $0.40 |
| Average True Range (ATR) | 0.06 | 0.02 |
| MACD | 0.02 | 0.01 |
| Stochastic Oscillator | 25.02 | 11.95 |
Tivic Health Systems Inc is a health technology company focused on developing and commercializing non-invasive bioelectronic medicine. The company's platform-based technology activates the body's own healing mechanisms and can be programmed to treat various disease conditions. company's products provide a natural alternative to the standard synthetic chemical methods used by the pharmaceutical industry. ClearUP Sinus Relief, is a first commercial product of the company which is a patented handled device that uses ultra-low current electrical waves to relieve sinus pain and congestion symptoms that are prevalent in nasal allergies, sinus infections, chronic sinusitis, cold and flu and other disease conditions.
Propanc Biopharma Inc is a development-stage healthcare company. It focuses on developing new cancer treatments for patients suffering from pancreatic, ovarian, and colorectal cancer. The company develops a rational, composite formulation of the anti-cancer compound, which together exert a number of effects designed to control or prevent tumors from recurring and spreading through the body. Its product, PRP, is a variation upon its novel formulation and involves proenzymes, the inactive precursors of enzymes.